Evidence map›Paper›PMID 33999322›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2021

The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia.

Ingrid A Cox, Barbara de Graaff, Hasnat Ahmed, Julie Campbell, Petr Otahal, Tamera J Corte, Ian Glaspole, Yuben Moodley, Nicole Goh, Sacha Macansh and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.The European journal of health economics : HEPAC : health economics in prevention and care · 2023
    Article
  4. Article
  5. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AQoL-8D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ingrid A CoxMenzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.ORCID http://orcid.org/0000-0001-5130-4088
Barbara de GraaffMenzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Hasnat AhmedMenzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Julie CampbellMenzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Petr OtahalMenzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Tamera J CorteNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia.
Ian GlaspoleNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia.
Yuben MoodleyFaculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia.
Nicole GohNHMRC Centre of Research Excellence for Pulmonary Fibrosis, Camperdown, Australia.
Sacha MacanshAustralian Idiopathic Pulmonary Fibrosis Registry, Lung Foundation of Australia, Camperdown, Australia.
E Haydn Walters *Menzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia.
Andrew J Palmer *Menzies Institute for Medical Research, The University of Tasmania, 17 Liverpool Street, Hobart, TAS, Australia. andrew.palmer@utas.edu.au.
University of Tasmania · AUThe Alfred Hospital · AULung Foundation Australia · AUThe University of Sydney · AUThe University of Western Australia · AU

Funding

National Health and Medical Research Council GNT1116371
6 · The paper itself

Abstract

purposeIdiopathic pulmonary fibrosis (IPF) is a progressive and universally fatal lung disease, characterised by increasing fibrosis of the lung parenchyma. In this study, we aimed to quantify the health state utility values (HSUVs) for Australians with IPF and to identify the factors affecting these HSUVs.

methodsParticipants of the Australian IPF Registry (AIPFR), with data on EuroQoL five dimension-five level (EQ-5D-5L) profiles were included. Pulmonary function tests (PFTs) were used to assess disease severity using three IPF -based classification systems. Stepwise multivariable linear regression models assessed the relationship between HSUVs and important demographic and clinical parameters.Query

resultsA total of 155 participants provided data for the analysis of HSUVs. For our base case, HSUVs ranged from - 0.57 to 1.00. Mean HSUVs for all participants was 0.65 (95% CI 0.61-0.70). In general, HSUVs decreased with increasing disease severity under all disease severity classification systems. Multivariable linear regression demonstrated a negative association between HSUVs, disease severity and having more than 2 comorbidities.

conclusionsOur study has shown that EQ-5D-5L has exhibited discriminatory sensitivity for the study population. We have demonstrated that disease severity and having more than two comorbidities was associated with lower HSUVs in Australians with IPF. Our findings support early diagnosis and appropriate evidence-based treatment to slow or prevent IPF progression; and identification and treatment of associated comorbidities to potentially improve health-related quality of life in people with IPF.

Indexed as

Idiopathic Pulmonary FibrosisQuality of LifeAustraliaHumansRegistriesSeverity of Illness IndexSurveys and QuestionnairesEQ-5D-5LEuroQol five dimensionHealth related quality of lifeHealth state utility valuesIdiopathic pulmonary fibrosis

Identifiers

PMID33999322
OpenAlexW3160045995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.